Jennifer Sorrell, MD
Pediatric Dermatology · Los Gatos, CANPI 1487827861
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.1% of the total across 729 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 13.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $3,015 and has fallen 52.6% since, to $1,429 in 2025.
Across 729 payments — averaging $18.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- LEO Pharma Inc.$1K
- Lilly USA, LLC$1K
- Johnson & Johnson$1K
- Sanofi$1K
- Regeneron Healthcare Solutions, Inc.$1K
- plus $6K from 24 others
What the payments were for
- Food & beverage$13,42997%
- Education$4013%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 86 | $1,859 |
| LEO Pharma Inc. | 127 | $1,451 |
| Lilly USA, LLC | 78 | $1,408 |
| Johnson & Johnson | 55 | $1,138 |
| Sanofi | 42 | $1,028 |
| Regeneron Healthcare Solutions, Inc. | 39 | $1,000 |
| Pfizer | 42 | $848 |
| Incyte Corporation | 55 | $823 |
| UCB, Inc. | 31 | $697 |
| Sun Pharmaceutical Industries Inc. | 29 | $688 |
| Amgen | 24 | $490 |
| Novartis | 18 | $423 |
| Galderma Laboratories, L.p. | 16 | $368 |
| Arcutis Biotherapeutics, Inc. | 25 | $332 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 11 | $223 |
| Dermavant Sciences, Inc. | 8 | $214 |
| Mayne Pharma Commercial LLC | 8 | $211 |
| VYNE Pharmaceuticals Inc. | 6 | $117 |
| Organon | 8 | $88 |
| Biofrontera Inc. | 6 | $77 |
| E.r. Squibb & Sons, L.L.C. | 2 | $68 |
| Janssen Scientific Affairs, LLC | 2 | $58 |
| Dermira, Inc. | 2 | $43 |
| Genentech USA, Inc. | 2 | $40 |
| Journey Medical Corporation | 2 | $36 |
| Organogenesis Inc. | 1 | $33 |
| Boehringer Ingelheim | 1 | $21 |
| EPI Health, LLC | 1 | $16 |
| Almirall LLC | 1 | $14 |
| DUSA Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COSENTYX$105
How this compares
$13,830 in reported general payments places this provider in the 75th percentile of 36 pediatric dermatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 27 | $103,378 |
| HumiraAdalimumab | 11 | $74,927 |
| Tacrolimus | 16 | $1,875 |
| Clobetasol Propionate | 40 | $1,590 |
| Triamcinolone Acetonide | 126 | $1,503 |
| Mometasone Furoate | 42 | $967 |
| Fluocinonide | 18 | $825 |
| Ketoconazole | 41 | $527 |
| Doxycycline Hyclate | 27 | $447 |
| Clindamycin Phosphate | 11 | $388 |
| Minoxidil | 25 | $309 |
| Hydrocortisone | 13 | $164 |
| ValacyclovirValacyclovir Hcl | 20 | $162 |
| Mupirocin | 24 | $159 |
| Terbinafine Hcl | 14 | $75 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieHumira | $1,859 | $74,92711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 36 pediatric dermatology providers in California.
Other pediatric dermatology in Los Gatos
- Lawrence EichenfieldSan Diego$2.8M
- Dawn EichenfieldSan Diego$252K
- Joyce TengPalo Alto$127K
- Brandie MetzIrvine$41K
- Shireen GuidePalo Alto$41K
- Ilka NetravaliPalo Alto$26K
- Maria BuetheOrange$20K
- Shehla AdmaniStanford$16K
- Dawn SiegelPalo Alto$11K
- Sheila FriedlanderSan Diego$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.